Abstract: Wound healing compositions comprising IL-1.alpha. and IL-1.beta. proteins in a physiologically acceptable hydrophilic vehicle are used to promote wound healing.

Abstract: There is disclosed a method for autologous hematopoietic cell transplantation of patients receiving cytoreductive therapy, comprising: (1) obtaining hematopoietic progenitor cells from bone marrow or peripheral blood from a patient prior to cytoreductive therapy; (2) expanding the hematopoietic progenitor cells ex vivo with an ex vivo growth factor selected from the group consisting of interleukin-3 (IL-3), steel factor (SF), granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin-1 (IL-1), GM-CSF/IL-3 fusion proteins and combinations thereof, to provide a cellular preparation comprising an expanded population of progenitor cells; and (3) administering the cellular preparation to the patient concurrently with or follwoing cytoreductive therapy.

Abstract: The present invention provides an isolated DNA sequence encoding soluble and membrane bound forms of a mammalian IgA Fc receptor, as well as recombinant expression vectors and host cells suitable for expressing the protein.

Abstract: Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed.

Abstract: Soluble human Interleukin-1 receptor proteins (shuIL-1Rs) and methods of using shuIL-1Rs to suppress immune or inflamatory responses in a mammal.

Abstract: A macrophage colony stimulating factor, M-CSF.gamma., which is a primary translation product of an alternative mRNA splicing event and is a precursor to biologically active M-CSF. DNA sequences encoding M-CSF.gamma. and recombinant expression vectors comprising the DNA sequences.

Abstract: Subjects suffering from infectious diseases are treated by direct administration of therapeutically-effective quantities of granulocyte-macrophage colony stimulating factor employed by itself or in conjunction with an antibiotic or a sulfonamide or other immunologically effective therapeutic agents. Homogeneous granulocyte-macrophage colony stimulating factor for use in treatment in bacterial diseases is prepared by recombinant DNA techniques and then purified to homogeneity by reverse phase high-performance liquid chromatography so that it may be safely administered to subject's suffering from infectious diseases.

Abstract: The present invention provides a pharmaceutical compositions comprising as active ingredients certain truncated purified human IL-3(Pro.sup.8 Asp.sup.15 Asp.sup.70) analog proteins expressed by transformed yeast of the species Saccharomyces cerevisiae, which when administered to a primate do not result in detectable urticaria.

Abstract: A DNA sequence encoding fusion protein is disclosed which comprises GM-CSF and IL-3. Such fusion proteins more biologically active than GM-CSF or IL-3 alone or GM-CSF and IL-3 combined.

Abstract: A process for preparing bovine interleukin I.beta. (bIL-1.beta.) by culturing a microbial host transformed by a vector containing a DNA sequence encoding bIL-1.beta. under conditions suitable for the expression of bIL-1.beta. and recovering bIL-1.beta..

Abstract: Cloning and expression of DNA segments encoding bovine GM-CSF, and processes for producing recombinant bovine GM-CSF as a product of recombinant cell culture, are disclosed.

Abstract: Mammalian Interleukin-1 receptor proteins (IL-1Rs), DNAs and expression vectors encoding mammalian IL-1Rs, and processes for producing mammalian IL-1Rs as products of cell culture, including recombinant systems, are disclosed.

Abstract: Macrophages and precursor monocytes are activated to exhibit tumoricidal activity by stimulation solely with granulocyte-macrophage colony stimulating factor. A patient suffering from tumors can be treated by direct administration of therapeutically effective quantities of activated granulocyte-macrophage colony stimulating factor. Homogeneous granulocyte-macrophage colony stimulating factor for use in activating macrophages and monocyte precursors is prepared by recombinant DNA techniques. The gene coding for granylocyte-macrophage colony stimulating factor is isolated and then recombinant protein product expressed in an appropriate expression system. The granulocyte-macrophage colony stimulating factor recovered from the expression system is purified to homogeneity by reverse phase high-performance liquid chromatography.

Abstract: A fusion protein is disclosed which comprises GM-CSF and IL-3. Such fusion proteins more biologically active than GM-CSF or IL-3 alone or GM-CSF and IL-3 combined.

Abstract: A process for purifying human G-CSF from an aqueous solution including the step of adding NaCl to the solution to selectively precipitate the human G-CSF.

Abstract: Methods for stimulating platelet production in mammals, comprising administration of interleukin-7 (IL-7), are disclosed.

Abstract: A particular calcium-dependent monoclonal antibody, 4E11, is produced from a murine hybridoma cell line and is useful for purifying a recombinant fusion protein having an N-terminal identification peptide DYKDDDDK to which the monoclonal antibody binds.

Abstract: A process for preparing bovine interleukin-2 (bIL-2) by culturing a microbial host transformed by a vector containing a DNA sequence encoding bIL-2 under conditions suitable for the expression of bIL-2 and recovering bIL-2.

Abstract: Mammalian Interleukin-1 receptor proteins (IL-1Rs), DNAs and expression vectors encoding mammalian IL-1Rs, and processes for producing mammalian IL-1Rs as products of cell culture, including recombinant systems, are disclosed.

Abstract: Cloning and expression of DNA segments encoding bovine IL-.alpha., and processes for producing purified bovine IL-1.alpha. as a product of recombinant cell culture, are disclosed.